PAHC Stock Analysis: Phibro Animal Health | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.301m USD | 12M Return: 6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.65M
EPS Trend: 95.2%
Qual. Beats: 3
Rev. Trend: 95.7%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Phibro Animal Health Corporation is a U.S.-based animal health and mineral nutrition company that operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company runs three reporting segments: Animal Health, Mineral Nutrition, and Performance Products, serving both livestock producers and companion animal markets.
The companys product portfolio includes antibacterials, anticoccidials, nutritional specialty products, vaccines (both conventionally licensed and autogenous), and vaccine adjuvants for poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also manufactures microbial and bioproducts for environmental, industrial, and agricultural applications, trace mineral formulations (zinc, copper, manganese, iron) for livestock feed fortification, and specialty ingredients used in personal care and industrial chemical industries.
Distribution occurs through local sales offices, integrated livestock producers, commercial animal feed manufacturers, wholesalers, and distributors. The company was founded in 1946 as Philipp Brothers Chemicals, Inc., adopted its current name in 2003, and is headquartered in Teaneck, New Jersey.
As a player in the animal pharmaceuticals and nutrition space, Phibro addresses the growing global demand for protein and the parallel rise in livestock health spending, while its Performance Products segment diversifies the business model beyond core animal health into industrial and specialty chemical end markets.
- Animal Health segment growth driven by vaccines and specialty nutrition
- High leverage and interest costs continue pressuring profit margins
- Antibiotic regulations and livestock production cycles shape end-market demand
| Net Income: 95.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.84 > 1.0 |
| NWC/Revenue: 40.81% < 20% (prev 42.79%; Δ -1.98% < -1%) |
| CFO/TA 0.05 > 3% & CFO 66.1m > Net Income 95.2m |
| Net Debt (761.9m) to EBITDA (225.3m): 3.38 < 3 |
| Current Ratio: 3.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 0.81% < -2% |
| Gross Margin: 32.54% > 18% (prev 31.67%; Δ 0.87% > 0.5%) |
| Asset Turnover: 108.6% > 50% (prev 90.39%; Δ 18.21% > 0%) |
| Interest Coverage Ratio: 3.81 > 6 (EBIT TTM 174.7m / Interest Expense TTM 45.9m) |
| A: 0.42 (Total Current Assets 894.1m - Total Current Liabilities 281.9m) / Total Assets 1.45b |
| B: 0.23 (Retained Earnings 336.1m / Total Assets 1.45b) |
| C: 0.13 (EBIT TTM 174.7m / Avg Total Assets 1.38b) |
| D: 0.33 (Book Value of Equity 361.8m / Total Liabilities 1.08b) |
| Altman-Z'' = 4.74 = AA |
| DSRI: 0.89 (Receivables 221.5m/197.5m, Revenue 1.50b/1.19b) |
| GMI: 0.97 (GM 31.67% / 32.54%) |
| AQI: 0.80 (AQ_t 0.10 / AQ_t-1 0.12) |
| SGI: 1.26 (Revenue 1.50b / 1.19b) |
| TATA: 0.02 (NI 95.2m - CFO 66.1m) / TA 1.45b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 33.00 with a total of 498,170 shares traded. Over the past week, the price has changed by -3.31%, over one month by +2.23%, over three months by -44.38% and over the past year by +5.95%.
Current recommended Stop Loss: 31.20 (which is 5.5% or 1.2 ATR below the current price).
Phibro Animal Health has received a consensus analysts rating of 2.50. Therefore, it is recommended to sell PAHC.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 45.6 | 38.2% |
P/E Trailing = 13.7639
P/E Forward = 13.8313
P/S = 0.8672
P/B = 3.6021
P/EG = 1.6791
Revenue TTM = 1.50b USD
EBIT TTM = 174.7m USD
EBITDA TTM = 225.3m USD
Long Term Debt = 712.7m USD (from longTermDebt, last quarter)
Short Term Debt = 32.2m USD (from shortTermDebt, last quarter)
Debt = 839.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.9m
Net Debt = 761.9m USD (calculated: Debt 839.4m - CCE 77.5m)
Enterprise Value = 2.06b USD (1.30b + Debt 839.4m - CCE 77.5m)
Interest Coverage Ratio = 3.81 (Ebit TTM 174.7m / Interest Expense TTM 45.9m)
EV/FCF = 161.5x (Enterprise Value 2.06b / FCF TTM 12.8m)
FCF Yield = 0.62% (FCF TTM 12.8m / Enterprise Value 2.06b)
FCF Margin = 0.85% (FCF TTM 12.8m / Revenue TTM 1.50b)
Net Margin = 6.35% (Net Income TTM 95.2m / Revenue TTM 1.50b)
Gross Margin = 32.54% ((Revenue TTM 1.50b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 32.77% (prev 35.48%)
Tobins Q-Ratio = 1.43 (Enterprise Value 2.06b / Total Assets 1.45b)
Interest Expense / Debt = 5.47% (Interest Expense 45.9m / Debt 839.4m)
Taxrate = 26.09% (33.6m / 128.9m)
NOPAT = 129.1m (EBIT 174.7m * (1 - 26.09%))
Current Ratio = 3.17 (Total Current Assets 894.1m / Total Current Liabilities 281.9m)
Debt / Equity = 2.32 (Debt 839.4m / totalStockholderEquity, last quarter 361.8m)
Debt / EBITDA = 3.38 (Net Debt 761.9m / EBITDA 225.3m)
Debt / FCF = 59.66 (Net Debt 761.9m / FCF TTM 12.8m)
Total Stockholder Equity = 322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.90% (Net Income 95.2m / Total Assets 1.45b)
RoE = 29.49% (Net Income TTM 95.2m / Total Stockholder Equity 322.9m)
RoCE = 16.87% (EBIT 174.7m / Capital Employed (Equity 322.9m + L.T.Debt 712.7m))
RoIC = 11.53% (NOPAT 129.1m / Invested Capital 1.12b)
WACC = 8.16% (E(1.30b)/V(2.14b) * Re(10.82%) + D(839.4m)/V(2.14b) * Rd(5.47%) * (1-Tc(0.26)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.19 | Cagr: 0.58%
[DCF] Terminal Value 73.10% ; FCFF base≈27.3m ; Y1≈23.9m ; Y5≈19.3m
[DCF] Fair Price = N/A (negative equity: EV 310.3m - Net Debt 761.9m = -451.6m; debt exceeds intrinsic value)
EPS Correlation: 95.18 | EPS CAGR: 47.10% | SUE: 0.91 | # QB: 3
Revenue Correlation: 95.68 | Revenue CAGR: 19.37% | SUE: 1.55 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.79 | Chg30d=-2.47% | Revisions=-25% | Analysts=1
EPS current Year (2026-06-30): EPS=3.07 | Chg30d=+1.59% | Revisions=+57% | GrowthEPS=+47.0% | GrowthRev=+15.6%
EPS next Year (2027-06-30): EPS=3.34 | Chg30d=-0.59% | Revisions=+17% | GrowthEPS=+8.8% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: +36% (up=6, down=2)